

Special Issue

2nd Edition: Treatment of Bone Metastasis

Message from the Guest Editor

This collection is the second edition of a previous Special Issue, entitled "Treatment of Bone Metastasis" (https://www.mdpi.com/journal/curroncol/special_issues/Treatment_Bone_Metastasis). We are pleased to invite submissions focusing on the following topics:

- Surveillance imaging and diagnostic work to ensure the accurate and timely identification of bone metastases.
- Current systemic treatment options with zoledronic acid and denosumab in order to provide knowledge of innovative techniques in evolving therapies.
- The role of interventional radiology: embolization, electro-chemotherapy, magnetic resonance imaging guided high-intensity focused ultrasound, and thermal ablation therapies.
- The search for possible prognostic factors affecting survival—the life expectancy of patients with bone metastases seems to be the most important factor in determining the surgical treatment, and in avoiding over- or under-treatments.
- The role of surgery: based on the risk of surgical complications, the patient's prognosis seems to be important regarding the type of surgical treatment in a patient with bone metastases.

Guest Editor

Dr. Costantino Errani

III Clinica di Ortopedia e Traumatologia, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy

Deadline for manuscript submissions

closed (15 July 2025)



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/si/182346](https://www.mdpi.com/si/182346)

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
curroncol](https://www.mdpi.com/journal/curroncol)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)